COLL Q2: ADHD Grew 41%, But NUCYNTA's 24% Slide Makes This a Watch, Not a Chase

ADHD momentum improved, but pain weakness still controls the near-term debate

What mattered in Q2

COLL's Q2 boiled down to one tension: the ADHD story improved, but the pain franchise still weighed on results. Management said ADHD growth helped offset some weakness, yet the company still reported $199.9 million in Q2 revenue and set $840 million in full-year revenue guidance after that. Full-year EBITDA guidance of $457.5 million also remained below Wall Street's expectations. That is why this still looks like a watch, not a chase. The market is no longer asking whether ADHD can grow; it is asking whether the growth can arrive quickly enough to replace revenue lost elsewhere.

The guidance matters because it is the scoreboard. Bulls can point to JORNAY PM revenue up 41% and note that AZSTARYS contributed $12.9 million in its first partial quarter, showing the diversification thesis has real traction. Bears can counter that the NUCYNTA franchise is still a meaningful drag. Until that drag is fully offset, the profit and cash-flow case still looks incomplete rather than ready for a straight rerating.

The real question is whether ADHD can replace pain fast enough

The mix shift is improving, but not yet decisive

The core question is not whether ADHD is growing. It is whether the newer ADHD engine can replace the older pain engine fast enough to support revenue and margins.

Right now, the pain business is still the larger piece, even if it is not weakening evenly across all products. That is why the mix matters more than any single headline. JORNAY PM is clearly accelerating, and AZSTARYS is already contributing meaningful incremental revenue. But the pain portfolio still needs to stabilize fast enough to give the ADHD growth story room to work.

Why the bull case looks more credible

The bull case is that ADHD growth is broad, not random. JORNAY PM revenue up 41% is not just a spike in demand; it suggests the product is still widening its reach.

AZSTARYS also matters because it expands the ADHD platform beyond a single launch. Contributing $12.9 million in its first partial quarter is a strong start, especially for a product that was only recently integrated. If that momentum holds, Collegium has a more credible diversification story than investors have had for some time.

Why the bear case still has weight

The bear case is about scale. A fast-growing ADHD franchise still has to offset a meaningful pain base before the market will stop worrying about decline risk. If NUCYNTA keeps sliding before ADHD is big enough to absorb the gap, the stock may remain a story name instead of a confirmed rerating candidate.

That is the setup to watch over the next few quarters: not whether ADHD works, but whether it works quickly enough.

Why the near-term call is still cautious

From here, COLL still looks more like a watchlist name than a chase. ADHD is already showing it can add real revenue, including AZSTARYS contributed $12.9 million in its first partial quarter. But investors still need evidence that the ADHD engine can carry the company before the pain franchise weakens further.

What to watch next

The next signposts are straightforward: - Does ADHD keep compounding quarter over quarter? - Does the pain portfolio stabilize instead of continuing to slip? - Does management's guidance start to look driven by ADHD strength rather than pain resilience?

If those pieces improve together, the mix will start to justify a more bullish read. If not, waiting is still the cleaner approach.